Keryx Biopharmaceuticals, Inc. to Host Conference Call on Fourth Quarter and Year End 2013 Financial Results
March 11 2014 - 4:30PM
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical
company focused on the acquisition, development and
commercialization of pharmaceutical products for the treatment of
renal disease, today announced that a conference call will be held
on Thursday, March 13, 2014 at 8:30 a.m. EDT to discuss results for
the fourth quarter and year ended December 31, 2013 and a business
outlook for 2014. Ron Bentsur, Chief Executive Officer of Keryx,
will host the call.
In order to participate in the conference call, please call
1-877-869-3847 (U.S.), 1-201-689-8261 (outside the U.S.), call-in
ID: KERYX. The audio recording of the conference call will be
available for replay at http://www.keryx.com, for a period of 15
days after the call.
Keryx will announce its financial results for this period in a
press release to be issued prior to the call.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals is focused on the acquisition,
development and commercialization of pharmaceutical products for
the treatment of renal disease. Keryx is developing Zerenex™
(ferric citrate coordination complex), an oral, ferric iron-based
compound. Zerenex has completed a U.S.-based Phase 3 clinical
program for the treatment of hyperphosphatemia (elevated phosphate
levels) in patients with chronic kidney disease on dialysis,
conducted pursuant to a Special Protocol Assessment agreement with
the FDA. Keryx's New Drug Application, submitted to the FDA in
2013, is currently under review and has an assigned Prescription
Drug User Fee Act (PDUFA) goal date of June 7, 2014. Keryx has
recently submitted a Marketing Authorization Application filing to
the European Medicines Agency. Zerenex has also completed a Phase 2
study in the U.S. for the management of elevated serum phosphorus
levels and iron deficiency anemia in patients with Stage 3 to 5
non-dialysis dependent chronic kidney disease. In addition, Keryx's
Japanese partner, Japan Tobacco, Inc. and Torii Pharmaceutical Co.,
Ltd., received marketing approval of ferric citrate in Japan for
the treatment of hyperphosphatemia in patients with chronic kidney
disease on January 17, 2014. Keryx is headquartered in New York
City.
CONTACT: KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Sep 2023 to Sep 2024